## APPENDIX 1  Voting frequency for trials (N=46)

| Trial                                                                 | n  | %  |
|-----------------------------------------------------------------------|----|----|
| Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF) | 27 | 59 |
| Cardiovascular and renal outcomes with empagliflozin in heart failure (EMPEROR-Reduced) | 22 | 48 |
| Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation (AUGUSTUS) | 16 | 35 |
| Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction (PARAGON-HF) | 11 | 24 |
| Antithrombotic therapy for atrial fibrillation with stable coronary disease (AFIRE) | 11 | 24 |
| Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT) | 11 | 24 |
| Efficacy and safety of low-dose colchicine after myocardial infarction (COLCOT) | 10 | 22 |
| Low-dose edoxaban in very elderly patients with atrial fibrillation (ELDERCARE) | 8  | 17 |
| Early rhythm-control therapy in patients with atrial fibrillation (EAST-AFNET 4) | 7  | 15 |
| Ticagrelor with or without aspirin in high-risk patients after PCI (TWILIGHT) | 7  | 15 |
| Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve (RIVER) | 6  | 13 |
| Colchicine in patients with chronic coronary disease (LoDoCo2) | 4  | 9  |
| Polypill with or without aspirin in persons without cardiovascular disease (TIPS-3) | 4  | 9  |
| Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk (STRENGTH) | 3  | 7  |
| Ticagrelor or prasugrel in patients with acute coronary syndromes (ISAR-REACT 5) | 3  | 7  |
| Vericiguat in patients with heart failure and reduced ejection fraction (VICTORIA) | 3  | 7  |
| Cardiovascular outcomes with ertugliflozin in type 2 diabetes (VERTIS CV) | 2  | 4  |
| Topic                                                                 | Score1 | Score2 |
|----------------------------------------------------------------------|--------|--------|
| Renin-angiotensin-aldosterone system blockers and the risk of COVID-19 | 2      | 4      |
| Ticagrelor in patients with stable coronary disease and diabetes (THEMIS) | 2      | 4      |

Barry AR, et al. Review of the top 5 cardiology studies of 2019-20. *Can Pharm J (Ott)* 2021;154. DOI: 10.1177/171516352111029328.